RADX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RA

Mkt Cap

$15.1M

Volume

106.38K

Loading chart

RA

RADXRadiopharm Theranostics Limited American Depositary Shares

RADX

Pay with—

Available Balance0.00

RA

Mkt Cap

$15.0M

Volume

106.38K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsRadiopharm Theranostics announced dosing of the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) at 70 mCi, following a positive recommendation from the Safety and Monitoring Committee. RV-01 is a 177Lutetium-tagged monoclonal antibody targeting B7-H3 in patients with B7-H3 expressing solid tumors, developed through a joint venture with MD Anderson Cancer Center.GlobeNewswire Inc. · Aug 26, 2026

Radiopharm Theranostics Reports Business UpdateRadiopharm Theranostics completed enrollment in its Phase 2b trial for RAD 101, an imaging agent for brain metastases, with interim data showing 90% concordance with MRI. The company also presented Phase 0/1 data for RAD 202 showing favorable safety and tumor uptake, received DSMC approval to advance to the next dose level, and initiated two new First-In-Human trials for radiotherapeutic assets RV-01 and RAD 402. Cash position declined to $19.2 million from $34.5 million in the prior quarter.GlobeNewswire Inc. · Apr 23, 2026

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical TrialRadiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to escalate its Phase 1 'HEAT' clinical trial of RAD202 to the next dose level of 130mCi in HER2-positive advanced solid tumor patients. The company remains on track to complete Phase 1 dose escalation by end of 2026.GlobeNewswire Inc. · Apr 8, 2026

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.Radiopharm Theranostics and Siemens Healthineers announced a supply agreement for RAD101, a novel PET imaging agent for brain metastases. The Phase 2b interim analysis showed 90% concordance with MRI (primary endpoint), with significant tumor uptake. Siemens will manufacture and distribute 18F-labeled RAD101 to support the upcoming Phase 3 registrational trial in the U.S.GlobeNewswire Inc. · Apr 7, 2026

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate CancerRadiopharm Theranostics announced the first patient dosing in a Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer treatment. Preclinical data showed strong tumor targeting with minimal bone/marrow uptake. The company plans to share data from the first two dose levels in H2 2026.GlobeNewswire Inc. · Mar 27, 2026

Radiopharm Theranostics Reports Half-Year Financial Results and Business UpdatesRadiopharm Theranostics announced interim Phase 2b results for RAD 101, with 92% of evaluable patients achieving the primary endpoint of MRI concordance in brain metastases imaging. The company also reported progress across its pipeline including DSMC approval for dose escalation in RAD 202 and RAD 204, FDA clearance for Phase 1 trials of RV 01 and RAD 402, and cash reserves of $34.52 million providing runway into 2027.GlobeNewswire Inc. · Jan 28, 2026

Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live streamEmergingGrowth.com has announced the complete schedule for the 89th Emerging Growth Conference taking place on January 21-22, 2026. The two-day virtual event will feature presentations from 40+ small-cap and emerging growth companies across sectors including biotech, mining, energy, and technology. Companies will present via video webcast with keynote speakers from each organization.GlobeNewswire Inc. · Jan 21, 2026

RAD Increases Ownership in Radiopharm Ventures to 87.5%Radiopharm Theranostics increased its ownership stake in Radiopharm Ventures (joint venture with MD Anderson Cancer Center) from 75% to 87.5%. The leading candidate Betabart, a B7H3-targeting monoclonal antibody, received FDA IND clearance and is expected to dose the first patient in Q1 2026 in a Phase I trial for solid tumors. Two additional preclinical assets show early positive results with final candidate selection planned for 2026.GlobeNewswire Inc. · Jan 12, 2026

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory BoardRadiopharm Theranostics has appointed Dr. Oliver Sartor, a renowned medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board to enhance its clinical research capabilities.GlobeNewswire Inc. · Jul 22, 2025

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid TumorsRadiopharm Theranostics has dosed the first patient in its Phase 1 'HEAT' clinical trial of RAD202, a nanobody targeting HER2-positive expression in advanced solid tumors. The trial aims to determine the recommended Phase 2 dose and evaluate the safety and preliminary efficacy of this radiotherapeutic.GlobeNewswire Inc. · Jun 4, 2025

to start trading

RA

RADXRadiopharm Theranostics Limited American Depositary Shares

RADX

Pay with—

Available Balance0.00

Your PositionYou don't own any RADX yet.

Related Tickers

Earnings